Johnson & Johnson (JNJ) 10-Q 30 Oct 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 27, 2015	Oct. 23, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	JOHNSON & JOHNSON
Entity Central Index Key	200,406
Current Fiscal Year End Date	--01-03
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 27, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		2,766,943,629

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 27, 2015	Dec. 28, 2014
Current assets:
Cash and cash equivalents	$ 13,639	$ 14,523
Marketable securities	23,667	18,566
Accounts receivable, trade, less allowances for doubtful accounts $260 (2014, $275)	11,366	10,985
Inventories (Note 2)	8,206	8,184
Deferred taxes on income	3,606	3,567
Prepaid expenses and other	3,010	3,486
Total current assets	63,494	59,311
Property, plant and equipment at cost	36,397	36,685
Less: accumulated depreciation	(20,846)	(20,559)
Property, plant and equipment, net	15,551	16,126
Intangible assets, net (Note 3)	25,988	27,222
Goodwill (Note 3)	21,279	21,832
Deferred taxes on income	3,150	3,396
Other assets	3,804	3,232
Total assets	133,266	131,119
Current liabilities:
Loans and notes payable	5,677	3,638
Accounts payable	5,928	7,633
Accrued liabilities	5,062	6,553
Accrued rebates, returns and promotions	5,338	4,010
Accrued compensation and employee related obligations	2,324	2,751
Accrued taxes on income	931	500
Total current liabilities	25,260	25,085
Long-term debt (Note 4)	14,073	15,122
Deferred taxes on income	3,561	3,154
Employee related obligations	9,515	9,972
Other liabilities	9,303	8,034
Total liabilities	61,712	61,367
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 7)	(12,861)	(10,722)
Retained earnings	102,748	97,245
Less: common stock held in treasury, at cost (352,562,000 and 336,620,000 shares)	21,453	19,891
Total shareholders’ equity	71,554	69,752
Total liabilities and shareholders' equity	$ 133,266	$ 131,119

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Millions	Sep. 27, 2015	Dec. 28, 2014
Current assets:
Allowances for doubtful accounts	$ 260	$ 275
Shareholders' equity:
Common stock, par value per share	$ 1	$ 1
Common stock, shares authorized	4,320,000	4,320,000
Common stock, shares issued	3,119,843	3,119,843
Treasury stock, shares	352,562	336,620

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2015	Sep. 28, 2014	Sep. 27, 2015	Sep. 28, 2014
Income Statement [Abstract]
Sales to customers (Note 9)	$ 17,102	$ 18,467	$ 52,263	$ 56,077
Sales to customers percent to sales	100.00%	100.00%	100.00%	100.00%
Cost of products sold	$ 5,224	$ 5,399	$ 15,863	$ 16,893
Cost of products sold percent to sales	30.50%	29.20%	30.40%	30.10%
Gross profit	$ 11,878	$ 13,068	$ 36,400	$ 39,184
Gross profit percent to sales	69.50%	70.80%	69.60%	69.90%
Selling, marketing and administrative expenses	$ 5,081	$ 5,468	$ 15,312	$ 16,132
Selling marketing and administrative expenses percent to sales	29.70%	29.60%	29.30%	28.80%
Research and development expense	$ 2,154	$ 2,023	$ 6,182	$ 5,859
Research and development expense percent to sales	12.60%	11.00%	11.80%	10.50%
In-process research and development	$ 10	$ 0	$ 10	$ 22
In-process research and development percent to sales	0.10%	0.00%	0.00%	0.00%
Interest income	$ (32)	$ (18)	$ (75)	$ (50)
Interest income percent to sales	(0.20%)	(0.10%)	(0.10%)	(0.10%)
Interest expense, net of portion capitalized	$ 123	$ 130	$ 392	$ 394
Interest expense, net of portion capitalized percent to sales	0.70%	0.70%	0.70%	0.70%
Other (income) expense, net	$ 420	$ (1,345)	$ (859)	$ (1,033)
Other (income) expense, net percent to sales	2.50%	(7.30%)	(1.60%)	(1.80%)
Earnings before provision for taxes on income	$ 4,122	$ 6,810	$ 15,438	$ 17,860
Earnings before provision for taxes on income percent to sales	24.10%	36.90%	29.50%	31.80%
Provision for taxes on income (Note 5)	$ 764	$ 2,061	$ 3,244	$ 4,058
Provision for taxes on income perent to sales	4.50%	11.20%	6.20%	7.20%
NET EARNINGS	$ 3,358	$ 4,749	$ 12,194	$ 13,802
Net earnings percent to sales	19.60%	25.70%	23.30%	24.60%
NET EARNINGS PER SHARE (Note 8)
Basic (per share)	$ 1.21	$ 1.69	$ 4.39	$ 4.89
Diluted (per share)	1.20	1.66	4.33	4.81
CASH DIVIDENDS PER SHARE	$ 0.75	$ 0.70	$ 2.20	$ 2.06
AVG. SHARES OUTSTANDING
Basic (shares)	2,768.4	2,814.4	2,774.8	2,822
Diluted (shares)	2,807.2	2,864.3	2,817.1	2,871.2

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2015	Sep. 28, 2014	Sep. 27, 2015	Sep. 28, 2014
Statement of Comprehensive Income [Abstract]
Net earnings	$ 3,358	$ 4,749	$ 12,194	$ 13,802
Other comprehensive income (loss), net of tax
Foreign currency translation	(1,069)	(2,400)	(2,729)	(2,499)
Securities:
Unrealized holding gain (loss) arising during period	(44)	(35)	267	6
Reclassifications to earnings	(46)	(1)	(127)	(1)
Net change	(90)	(36)	140	5
Employee benefit plans:
Prior service cost amortization during period	(5)	(5)	(16)	(14)
Gain (loss) amortization during period	159	101	477	301
Net change	154	96	461	287
Derivatives & hedges:
Unrealized gain (loss) arising during period	160	14	26	(139)
Reclassifications to earnings	38	(49)	(37)	(176)
Net change	198	(35)	(11)	(315)
Other comprehensive income (loss)	(807)	(2,375)	(2,139)	(2,522)
Comprehensive income	$ 2,551	$ 2,374	$ 10,055	$ 11,280

Consolidated Statements of Com6

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2015	Sep. 28, 2014	Sep. 27, 2015	Sep. 28, 2014
Consolidated Statement of Comprehensive Income [Abstract]
Securities	$ 48	$ 19	$ 76	$ 3
Employee Benefits	75	46	226	139
Derivatives & Hedges	$ 107	$ 19	$ 6	$ 170

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 27, 2015	Sep. 28, 2014
CASH FLOW FROM OPERATING ACTIVITIES
Net earnings	$ 12,194	$ 13,802
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	2,713	2,904
Stock based compensation	677	646
Venezuela adjustments	0	89
Asset write-downs	367	259
Net gain on sale of assets/businesses	(1,274)	(2,336)
Deferred tax provision	233	297
Accounts receivable allowances	2	(54)
Changes in assets and liabilities, net of effects from acquisitions:
Increase in accounts receivable	(910)	(399)
Increase in inventories	(719)	(1,098)
Decrease in accounts payable and accrued liabilities	(1,558)	(827)
Decrease in other current and non-current assets	986	72
Increase in other current and non-current liabilities	1,486	751
NET CASH FLOWS FROM OPERATING ACTIVITIES	14,197	14,106
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(2,097)	(2,218)
Proceeds from the disposal of assets/businesses, net	1,620	4,481
Acquisitions, net of cash acquired	(233)	(291)
Purchases of investments	(28,766)	(25,784)
Sales of investments	23,167	14,576
Other	(35)	(147)
NET CASH USED BY INVESTING ACTIVITIES	(6,344)	(9,383)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders	(6,101)	(5,812)
Repurchase of common stock	(3,394)	(4,381)
Proceeds from short-term debt	2,107	629
Retirement of short-term debt	(930)	(1,713)
Proceeds from long-term debt	3	17
Retirement of long-term debt	(27)	(1,787)
Proceeds from the exercise of stock options/excess tax benefits	837	1,406
Other	(50)	0
NET CASH USED BY FINANCING ACTIVITIES	(7,555)	(11,641)
Effect of exchange rate changes on cash and cash equivalents	(1,182)	(191)
Decrease in cash and cash equivalents	(884)	(7,109)
Cash and Cash equivalents, beginning of period	14,523	20,927
CASH AND CASH EQUIVALENTS, END OF PERIOD	13,639	13,818
Acquisitions
Fair value of assets acquired	477	305
Fair value of liabilities assumed and non-controlling interests	(244)	(14)
Net fair value of acquisitions	$ 233	$ 291

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 27, 2015
Accounting Policies [Abstract]
New Accounting Pronouncements And Other	The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2014 . The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. During the fiscal third quarter of 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update 2015-16 Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The amendments in this update require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This update will be effective for the Company for all annual and interim periods beginning after December 15, 2015. The amendments in this update should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update with earlier application permitted for financial statements that have not been issued. This update is not expected to have a material impact on the Company’s consolidated financial statements. During the fiscal second quarter of 2015, the FASB issued Accounting Standard Update 2015-11: Simplifying the Measurement of Inventory. This update requires inventory to be measured at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. This update will be effective for the Company for all annual and interim periods beginning after December 15, 2016. The amendments in this update should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. This update will not have a material impact on the presentation of the Company’s financial position. During the fiscal second quarter of 2015, the FASB issued Accounting Standard Update 2015-03: Simplifying the Presentation of Debt Issuance Costs. This update requires capitalized debt issuance costs to be presented as a reduction to the carrying value of debt instead of being classified as a deferred charge, as currently required. This update will be effective for the Company for all annual and interim periods beginning after December 15, 2015 and is required to be applied retroactively for all periods presented. This update will not have a material impact on the presentation of the Company’s financial position. During the fiscal second quarter of 2015, the FASB issued Accounting Standard Update 2015-04: Practical Expedient for the Measurement Date of an Employer’s Defined Benefit Obligation and Plan Assets. This update provides a practical expedient option to entities that have defined benefit plans and have a fiscal year-end that does not coincide with a calendar month-end. This option allows an entity to elect to measure defined benefit plan assets and obligations using the calendar month-end that is closest to its fiscal year-end. This update will be effective for the Company for all annual and interim periods beginning after December 15, 2015 and if the practical expedient is elected by an entity, it is required to be adopted on a prospective basis. Early adoption is permitted. The Company has elected to adopt the practical expedient to measure its defined benefit plans. This election is not expected to have a material impact on the Company’s consolidated financial statements. During the fiscal second quarter of 2014, the FASB issued Accounting Standards Update 2014-09: Revenue from Contracts with Customers. This standard replaces substantially all current revenue recognition accounting guidance. During the fiscal third quarter of 2015, the FASB approved a one year deferral to the effective date of Accounting Standards Update No. 2014-09 to be adopted by all public companies for all annual periods and interim reporting periods beginning after December 15, 2017. Early adoption of this standard is permitted but not before the original effective for the year beginning after December 15, 2016. The Company is currently assessing the impact of the future adoption of this standard on its financial statements. During the fiscal second quarter of 2014, the FASB issued amended guidance Accounting Standards Update No. 2014-10: Development Stage Entities: Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entity Guidance in Topic 810, Consolidation. The change in the current guidance will require the Company to determine if it should consolidate one of these entities based on the change in the consolidation analysis. This update to the consolidation analysis will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The adoption of this standard is not expected to have a material impact on the presentation of the Company's results of operations, cash flows or financial position. During the fiscal third quarter of 2014, the FASB issued Accounting Standards Update No. 2014-15: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This standard requires management to evaluate, for each annual and interim reporting period, whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued or are available to be issued. If substantial doubt is raised, additional disclosures around management’s plan to alleviate these doubts are required. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2016. This standard is not expected to have any impact on current disclosures in the financial statements. Annual Closing Date The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks, as is the case in 2015.

Inventories

Inventories	9 Months Ended
	Sep. 27, 2015
Inventory Disclosure [Abstract]
Inventories	INVENTORIES (Dollars in Millions) September 27, 2015 December 28, 2014 Raw materials and supplies $ 1,198 1,214 Goods in process 2,026 2,461 Finished goods 4,982 4,509 Total inventories $ 8,206 8,184

Intangible Assets and Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Sep. 27, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2014 . Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted. (Dollars in Millions) September 27, 2015 December 28, 2014 Intangible assets with definite lives: Patents and trademarks — gross $ 8,298 9,074 Less accumulated amortization 4,687 4,700 Patents and trademarks — net 3,611 4,374 Customer relationships and other intangibles — gross 17,739 17,970 Less accumulated amortization 5,637 5,227 Customer relationships and other intangibles — net 12,102 12,743 Intangible assets with indefinite lives: Trademarks 7,084 7,263 Purchased in-process research and development 3,191 2,842 Total intangible assets with indefinite lives 10,275 10,105 Total intangible assets — net $ 25,988 27,222 Goodwill as of September 27, 2015 was allocated by segment of business as follows: (Dollars in Millions) Consumer Pharm Med Devices Total Goodwill, net at December 28, 2014 $ 7,675 2,626 11,531 21,832 Goodwill, related to acquisitions — 64 22 86 Goodwill, related to divestitures (117 ) (17 ) (1 ) (135 ) Currency translation/Other (350 ) (56 ) (98 ) (1) (504 ) Goodwill, net as of September 27, 2015 $ 7,208 2,617 11,454 21,279 See Note 10 to the Consolidated Financial Statements for more details related to business combinations and divestitures. (1) Includes $98 million classified as held for sale, a component of other assets on the Consolidated Balance Sheet, related to the divestiture of Cordis which was pending as of September 27, 2015. The weighted average amortization periods for patents and trademarks and customer relationships and other intangible assets are 17 years and 24 years, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $912 million and $1,033 million for the fiscal nine months ended September 27, 2015 and September 28, 2014 , respectively. The estimated amortization expense for the five succeeding years approximates $1.2 billion , before tax, per year. Intangible asset write-downs are included in Other (income) expense, net.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 27, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are treated as fair value hedges. The Company may use forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features or requirements to post collateral by either the Company or the counter-party. On an ongoing basis, the Company monitors counterparty credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an "A" (or equivalent) credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this note for receivables and payables with these commercial institutions. As of September 27, 2015 , the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $27.8 billion , $2.4 billion and $2.2 billion , respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Changes in the fair value of a derivative that is designated as a cash flow hedge and is highly effective are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account and are insignificant. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is included in current period earnings in Other (income) expense, net for forward foreign exchange contracts and cross currency interest rate swaps. For interest rate swaps designated as fair value hedges, hedge ineffectiveness, if any, is included in current period earnings within interest expense. For the current reporting period, hedge ineffectiveness associated with interest rate swaps were not material. As of September 27, 2015 , the balance of deferred net gains on derivatives included in accumulated other comprehensive income was $130 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months , excluding interest rate contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives designated as cash flow hedges for the fiscal third quarters in 2015 and 2014 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal Third Quarters Ended Cash Flow Hedges By Income Statement Caption September 27, 2015 September 28, 2014 September 27, 2015 September 28, 2014 September 27, 2015 September 28, 2014 Sales to customers (3) $ 3 (43 ) (24 ) (2 ) (3 ) — Cost of products sold (3) 222 (37 ) (34 ) 37 1 (2 ) Research and development expense (3) (10 ) 25 7 8 — — Interest (income)/Interest expense, net (4) (13 ) 11 1 (6 ) — — Other (income) expense, net (3) (42 ) 58 12 12 (1 ) — Total $ 160 14 (38 ) 49 (3 ) (2 ) The following table is a summary of the activity related to derivatives designated as cash flow hedges for the first fiscal nine months in 2015 and 2014 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal Nine Months Ended Cash Flow Hedges By Income Statement Caption September 27, 2015 September 28, 2014 September 27, 2015 September 28, 2014 September 27, 2015 September 28, 2014 Sales to customers (3) $ (52 ) (73 ) (95 ) 6 (5 ) 1 Cost of products sold (3) 106 (187 ) 82 196 15 (4 ) Research and development expense (3) (13 ) 28 (2 ) (5 ) — (1 ) Interest (income)/Interest expense, net (4) (42 ) 21 (2 ) (12 ) — — Other (income) expense, net (3) 27 72 54 (9 ) — — Total $ 26 (139 ) 37 176 10 (4 ) All amounts shown in the table above are net of tax. (1) Effective portion (2) Ineffective portion (3) Forward foreign exchange contracts (4) Cross currency interest rate swaps For the fiscal third quarters ended September 27, 2015 and September 28, 2014 , a loss of $8 million and a loss of $2 million , respectively, was recognized in Other (income) expense, net, relating to forward foreign exchange contracts not designated as hedging instruments. For the fiscal nine months ended September 27, 2015 and September 28, 2014 , a gain of $32 million and a loss of $48 million , respectively, was recognized in Other (income) expense, net, relating to forward foreign exchange contracts not designated as hedging instruments. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 having the highest priority and Level 3 having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company did not have any other significant financial assets or liabilities which would require revised valuations under this standard that are recognized at fair value. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of September 27, 2015 and December 28, 2014 were as follows: September 27, 2015 December 28, 2014 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts (7) $ — 791 — 791 996 Interest rate contracts (2)(4)(7) — 51 — 51 31 Total — 842 — 842 1,027 Liabilities: Forward foreign exchange contracts (8) — 472 — 472 751 Interest rate contracts (3)(4) — 185 — 185 8 Total — 657 — 657 759 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts (7) — 56 — 56 29 Liabilities: Forward foreign exchange contracts (8) — 39 — 39 51 Available For Sale Other Investments: Equity investments (5) 1,130 — — 1,130 679 Debt securities (6) $ — 5,269 — 5,269 — (1) 2014 assets and liabilities are all classified as Level 2 with the exception of equity investments of $679 million , which are classified as Level 1. (2) Includes $45 million and $29 million of non-current other assets for September 27, 2015 and December 28, 2014, respectively. (3) Includes $185 million and $8 million of non-current other liabilities for September 27, 2015 and December 28, 2014, respectively. (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets. The carrying amount of the equity investments were $531 million and $284 million as of September 27, 2015 and December 28, 2014, respectively. The unrealized gains were $648 million and $406 million as of September 27, 2015 and December 28, 2014, respectively. The unrealized losses were $49 million and $11 million as of September 27, 2015 and December 28, 2014, respectively. (6) Classified as current marketable securities. (7) Classified as other current assets. (8) Classified as accounts payable. The Company's cash, cash equivalents and current marketable securities as of September 27, 2015 comprised: September 27, 2015 (Dollars in Millions) Carrying Amount Unrealized Gain Unrealized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 1,976 — — 1,976 1,976 U.S. Gov't Securities (1) 15,694 5 — 15,699 1,700 13,994 Other Sovereign Securities (1) 2,737 — — 2,737 1,192 1,545 U.S. Reverse repurchase agreements (1) 3,015 — — 3,015 3,015 Other Reverse repurchase agreements (1) 2,179 — — 2,179 2,179 Corporate debt securities (1) 4,237 — — 4,237 1,378 2,859 Money market funds 1,358 — — 1,358 1,358 Time deposits (1) 841 — — 841 841 Subtotal 32,037 5 — 32,042 13,639 18,398 Gov't Securities 4,255 14 (1 ) 4,268 — 4,268 Corporate debt securities 1,002 2 (3 ) 1,001 — 1,001 Subtotal Available for Sale (2) $ 5,257 16 (4 ) 5,269 — 5,269 Total cash, cash equivalents and current marketable securities 13,639 23,667 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs. The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available for current operations and are classified as current marketable securities. The estimated fair value was the same as the amortized cost as of December 28, 2014. The contractual maturities of the debt securities available for sale at September 27, 2015 are due from one year through five years. Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of September 27, 2015 : (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 5,677 5,677 Non-Current Debt 3 month LIBOR+0.07% FRN due 2016 800 800 0.70% Notes due 2016 399 400 5.55% Debentures due 2017 1,000 1,084 1.125% Notes due 2017 706 710 5.15% Debentures due 2018 899 995 1.65% Notes due 2018 609 616 4.75% Notes due 2019 (1B Euro 1.1267) 1,123 1,322 1.875% Notes due 2019 510 517 3% Zero Coupon Convertible Subordinated Debentures due in 2020 140 181 2.95% Debentures due 2020 545 585 3.55% Notes due 2021 448 487 2.45% Notes due 2021 350 357 6.73% Debentures due 2023 250 326 3.375% Notes due 2023 811 856 5.50% Notes due 2024 (500 MM GBP 1.5215) 756 940 6.95% Notes due 2029 297 426 4.95% Debentures due 2033 500 571 4.375% Notes due 2033 864 932 5.95% Notes due 2037 996 1,275 5.85% Debentures due 2038 700 898 4.50% Debentures due 2040 541 585 4.85% Notes due 2041 298 345 4.50% Notes due 2043 499 539 Other 32 32 Total Non-Current Debt $ 14,073 15,779 The weighted average effective interest rate on non-current debt is 4.18% . The excess of the fair value over the carrying value of debt was $2.2 billion at December 28, 2014. Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 27, 2015
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The worldwide effective income tax rates for the fiscal nine months of 2015 and 2014 were 21.0% and 22.7% , respectively. The lower effective tax rate in 2015 as compared to 2014 was primarily due to the 2014 divestiture of the Ortho-Clinical Diagnostics business at an approximate 41.0% effective tax rate and the accrual of an additional year of the Branded Prescription Drug Fee, which is not tax deductible. This additional 2014 tax expense was partially offset by a benefit from the Conor Medsystems divestiture, a settlement of substantially all issues related to the Company's U.S. Internal Revenue Service audit of tax years 2006 - 2009 and the federal appeals court’s decision in OMJ Pharmaceuticals, Inc.’s litigation regarding credits under former Section 936 of the Internal Revenue Code. Additionally, the effective tax rate is lower in 2015 as compared to 2014 as a result of the mix in foreign earnings to lower tax jurisdictions. As of September 27, 2015 , the Company had approximately $2.6 billion of liabilities from unrecognized tax benefits. The Company believes it is possible that audits may be completed by tax authorities in some jurisdictions over the next twelve months. The Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.

Pensions and Other Postretireme

Pensions and Other Postretirement Benefits	9 Months Ended
	Sep. 27, 2015
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure	PENSIONS AND OTHER POSTRETIREMENT BENEFITS Components of Net Periodic Benefit Cost Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the fiscal third quarters of 2015 and 2014 include the following components: Fiscal Third Quarters Ended Retirement Plans Other Benefit Plans (Dollars in Millions) September 27, 2015 September 28, 2014 September 27, 2015 September 28, 2014 Service cost $ 247 197 64 52 Interest cost 246 255 46 50 Expected return on plan assets (451 ) (403 ) (2 ) (2 ) Amortization of prior service cost/(credit) — 1 (8 ) (8 ) Recognized actuarial losses 186 115 50 33 Curtailments and settlements — (11 ) — — Net periodic benefit cost $ 228 154 150 125 Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the fiscal nine months of 2015 and 2014 include the following components: Fiscal Nine Months Ended Retirement Plans Other Benefit Plans (Dollars in Millions) September 27, 2015 September 28, 2014 September 27, 2015 September 28, 2014 Service cost $ 744 594 193 158 Interest cost 743 768 139 149 Expected return on plan assets (1,361 ) (1,212 ) (5 ) (5 ) Amortization of prior service cost/(credit) 1 4 (25 ) (25 ) Recognized actuarial losses 560 346 150 101 Curtailments and settlements 4 (11 ) — — Net periodic benefit cost $ 691 489 452 378 Company Contributions For the fiscal nine months ended September 27, 2015 , the Company contributed $316 million and $23 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 27, 2015
Equity [Abstract]
Accumulated Other Comprehensive Income	ACCUMULATED OTHER COMPREHENSIVE INCOME Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) December 28, 2014 $ (4,803 ) 257 (6,317 ) 141 (10,722 ) Net change (2,729 ) 140 461 (11 ) (2,139 ) September 27, 2015 $ (7,532 ) 397 (5,856 ) 130 (12,861 ) Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction. See Note 4 for additional details.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 27, 2015
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal third quarters ended September 27, 2015 and September 28, 2014 : Fiscal Third Quarters Ended (Shares in Millions) September 27, 2015 September 28, 2014 Basic net earnings per share $ 1.21 1.69 Average shares outstanding — basic 2,768.4 2,814.4 Potential shares exercisable under stock option plans 129.4 148.4 Less: shares which could be repurchased under treasury stock method (92.8 ) (101.2 ) Convertible debt shares 2.2 2.7 Average shares outstanding — diluted 2,807.2 2,864.3 Diluted earnings per share $ 1.20 1.66 The diluted earnings per share calculation for both the fiscal third quarters ended September 27, 2015 and September 28, 2014 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense. The diluted net earnings per share calculation for the fiscal third quarter ended September 27, 2015 excluded 20 million shares related to stock options, as the exercise price of these options was greater than their average market value, which would result in an anti-dilutive effect on diluted earnings per share. Diluted earnings per share calculation for the fiscal third quarter ended September 28, 2014 included all shares related to stock options, as there were no options or other instruments which were anti-dilutive. The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal nine months ended September 27, 2015 and September 28, 2014 : Fiscal Nine Months Ended (Shares in Millions) September 27, 2015 September 28, 2014 Basic net earnings per share $ 4.39 4.89 Average shares outstanding — basic 2,774.8 2,822.0 Potential shares exercisable under stock option plans 129.1 148.8 Less: shares which could be repurchased under treasury stock method (89.0 ) (102.3 ) Convertible debt shares 2.2 2.7 Average shares outstanding — diluted 2,817.1 2,871.2 Diluted earnings per share $ 4.33 4.81 The diluted earnings per share calculation for both the fiscal nine months ended September 27, 2015 and September 28, 2014 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense. The diluted net earnings per share calculation for the fiscal nine months ended September 27, 2015 excluded 20 million shares related to stock options, as the exercise price of these options was greater than their average market value, which would result in an anti-dilutive effect on diluted earnings per share. Diluted net earnings per share calculation for the fiscal nine months ended September 28, 2014 included all shares related to stock options, as there were no options or other instruments which were anti-dilutive.

Segments of Business and Geogra

Segments of Business and Geographic Areas	9 Months Ended
	Sep. 27, 2015
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS Fiscal Third Quarters Ended (Dollars in Millions) September 27, September 28, Percent Change Consumer United States $ 1,277 1,173 8.9 % International 2,037 2,416 (15.7 ) Total 3,314 3,589 (7.7 ) Pharmaceutical United States 4,509 4,723 (4.5 ) International 3,185 3,584 (11.1 ) Total 7,694 8,307 (7.4 ) Medical Devices United States 3,005 2,946 2.0 International 3,089 3,625 (14.8 ) Total 6,094 6,571 (7.3 ) Worldwide United States 8,791 8,842 (0.6 ) International 8,311 9,625 (13.7 ) Total $ 17,102 18,467 (7.4 )% Fiscal Nine Months Ended (Dollars in Millions) September 27, September 28, Percent Change Consumer United States $ 3,991 3,802 5.0 % International 6,196 7,088 (12.6 ) Total 10,187 10,890 (6.5 ) Pharmaceutical United States 13,423 13,076 2.7 International 9,943 11,238 (11.5 ) Total 23,366 24,314 (3.9 ) Medical Devices United States 8,980 9,300 (3.4 ) International 9,730 11,573 (15.9 ) Total 18,710 20,873 (10.4 ) Worldwide United States 26,394 26,178 0.8 International 25,869 29,899 (13.5 ) Total $ 52,263 56,077 (6.8 )% SEGMENT PRE-TAX PROFIT Fiscal Third Quarters Ended (Dollars in Millions) September 27, September 28, Percent Change Consumer (1) $ 811 407 99.3 % Pharmaceutical (2) 2,732 3,247 (15.9 ) Medical Devices (3) 835 3,399 (75.4 ) Segments operating profit 4,378 7,053 (37.9 ) Less: Expense not allocated to segments (4) 256 243 Worldwide income before taxes $ 4,122 6,810 (39.5 )% Fiscal Nine Months Ended (Dollars in Millions) September 27, 2015 September 28, 2014 Percent Change Consumer (1) $ 1,772 1,588 11.6 % Pharmaceutical (2) 9,816 9,921 (1.1 ) Medical Devices (3) 4,640 7,069 (34.4 ) Segments operating profit 16,228 18,578 (12.6 ) Less: Expense not allocated to segments (4) 790 718 Worldwide income before taxes $ 15,438 17,860 (13.6 )% (1) Includes a gain of $229 million from the divestiture of the SPLENDA ® brand recorded in the fiscal third quarter and fiscal nine months of 2015. Includes a gain of $388 million from the divestiture of the K-Y ® brand recorded in the fiscal nine months of 2014. (2) Includes litigation expense of $136 million in the fiscal nine months of 2015. Includes a gain of $981 million recorded in the fiscal nine months of 2015 from the divestiture of the U.S. license rights to NUCYNTA ® (tapentadol), NUCYNTA ® ER (tapentadol extended-release tablets), and NUCYNTA ® (tapentadol) oral solution. Includes an additional year of the Branded Prescription Drug Fee of $220 million recorded in the fiscal third quarter and fiscal nine months of 2014. (3) Includes litigation expense of $409 million related to product liability and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal third quarter of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $225 million , Synthes integration costs of $167 million and $126 million for costs associated with the DePuy ASR TM Hip program recorded in the fiscal third quarter of 2014. Includes $148 million for costs associated with the DePuy ASR TM Hip program, Synthes integration costs of $113 million and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal nine months of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $501 million , Synthes integration costs of $429 million and $126 million for costs associated with the DePuy ASR TM Hip program recorded in the fiscal nine months of 2014. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA Fiscal Third Quarters Ended (Dollars in Millions) September 27, 2015 September 28, 2014 Percent Change United States $ 8,791 8,842 (0.6 )% Europe 3,802 4,446 (14.5 ) Western Hemisphere, excluding U.S. 1,463 1,820 (19.6 ) Asia-Pacific, Africa 3,046 3,359 (9.3 ) Total $ 17,102 18,467 (7.4 )% Fiscal Nine Months Ended (Dollars in Millions) September 27, 2015 September 28, 2014 Percent Change United States $ 26,394 26,178 0.8 % Europe 11,993 14,387 (16.6 ) Western Hemisphere, excluding U.S. 4,603 5,378 (14.4 ) Asia-Pacific, Africa 9,273 10,134 (8.5 ) Total $ 52,263 56,077 (6.8 )%

Business Combinations and Dives

Business Combinations and Divestitures	9 Months Ended
	Sep. 27, 2015
Business Combinations [Abstract]
Business Combinations and Divestitures	BUSINESS COMBINATIONS AND DIVESTITURES Subsequent to the quarter, on October 2, 2015, the Company completed the divestiture of the Cordis business to Cardinal Health for an approximate value of $2.0 billion subject to customary adjustments. The Company will record the gain in the fiscal fourth quarter of 2015. As of September 27, 2015, the assets classified as held for sale relating to the Cordis business were $173 million of inventory classified as prepaid expenses and other on the Consolidated Balance Sheet. The non-current assets classified as held for sale relating to the Cordis business were $104 million of property, plant and equipment, net, $59 million of intangible assets and $98 million of goodwill classified as other assets on the Consolidated Balance Sheet. During the fiscal third quarter of 2015, the Company completed the divestiture of its SPLENDA ® brand to Heartland Food Products Group. The pre-tax gain on the divestiture was $229 million and was recognized in Other (income) expense, net. During the fiscal second quarter of 2015, the Company completed the divestiture of its U.S. license rights to NUCYNTA ® (tapentadol), NUCYNTA ® ER (tapentadol extended-release tablets), and NUCYNTA ® (tapentadol) oral solution for approximately $1.05 billion . The pre-tax gain on the divestiture was $981 million and was recognized in Other (income) expense, net. During the fiscal first quarter of 2015, the Company acquired XO1 Limited, a privately-held biopharmaceutical company developing the anti-thrombin antibody, ichorcumab. During the fiscal third quarter of 2014, the Company divested its Ortho-Clinical Diagnostics business to The Carlyle Group, for approximately $4.0 billion . The Company recorded a pre-tax net gain of approximately $1.9 billion in the fiscal third quarter of 2014. As of September 27, 2015, the assets classified as held for sale relating to the Ortho-Clinical Diagnostics companies in countries that have not completely closed due to local regulatory requirements were $42 million of inventory, classified as prepaid expenses and other on the Consolidated Balance Sheet and $107 million of property, plant and equipment, classified as other assets on the Consolidated Balance Sheet. Additional countries are expected to close by the end of the year. During the fiscal third quarter of 2014, the Company completed the acquisition of Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb ® technology platform. During the fiscal second quarter of 2014, McNEIL-PPC, Inc., a subsidiary of Johnson & Johnson, completed the divestiture of the K-Y ® brand to Reckitt Benckiser Group PLC in the U.S. and certain other markets. The pre-tax gain on the divestiture in the countries that closed as of the fiscal third quarter of 2014 was $388 million and was recognized in Other (income) expense, net.

Legal Proceedings

Legal Proceedings	9 Months Ended
	Sep. 27, 2015
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	LEGAL PROCEEDINGS Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. The Company records accruals for such contingencies when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of September 27, 2015, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to determine an estimate of the possible loss or range of loss beyond the amounts already accrued. These matters can be affected by various factors, including whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; or there are numerous parties involved. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution in any reporting period of one or more of these matters, either alone or in the aggregate, may have a material adverse effect on the Company's results of operations and cash flows for that period. PRODUCT LIABILITY Certain subsidiaries of Johnson & Johnson are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While these subsidiaries believe they have substantial defenses, it is not feasible to predict the ultimate outcome of litigation. The Company has established product liability accruals in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. In addition, product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System, the PINNACLE ® Acetabular Cup System, pelvic meshes, RISPERDAL ® , and XARELTO ® . As of September 27, 2015, in the U.S. there were approximately 6,300 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System, 8,300 with respect to the PINNACLE ® Acetabular Cup System, 44,400 with respect to pelvic meshes, 5,400 with respect to RISPERDAL ® , and 3,000 with respect to XARELTO ® . In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in Federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada and Australia. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR™ Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. This settlement covered approximately 8,000 patients. In February 2015, DePuy reached an additional agreement which would effectively extend the existing settlement program to ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 1, 2015. This second agreement is now estimated to cover approximately 1,800 additional patients. The estimated cost of these agreements is covered by existing accruals. This settlement program is expected to bring to a close significant ASR Hip litigation activity in the U.S. However, many lawsuits in the U.S. will remain, and the settlement program does not address litigation outside of the U.S. The Company continues to receive information with respect to potential costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the DePuy ASR™ Hip program and related product liability litigation. Updates to these accruals may be required in the future as additional information becomes available. Claims for personal injury have also been made against DePuy and Johnson & Johnson relating to DePuy's PINNACLE ® Acetabular Cup System used in hip replacement surgery. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom. The Company has established an accrual to cover defense costs in connection with product liability litigation associated with DePuy's PINNACLE ® Acetabular Cup System. Changes to this accrual may be required in the future as additional information becomes available. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Southern District of West Virginia. In addition, class actions and individual personal injury cases or claims have been commenced in Australia, Belgium, Canada, England, Israel, Italy, the Netherlands, Scotland and Venezuela, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices. The Company has established an accrual with respect to product liability litigation associated with Ethicon's pelvic mesh products. Changes to this accrual may be required in the future as additional information becomes available. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL ® , indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism, and related compounds. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established an accrual with respect to product liability litigation associated with RISPERDAL ® . Changes to this accrual may be required in the future as additional information becomes available. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of XARELTO ® , an oral anticoagulant. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States and many cases have been consolidated into a state mass tort litigation in Philadelphia, Pennsylvania. Class action lawsuits also have been filed in Canada. The Company has established an accrual with respect to product liability litigation associated with XARELTO ® . Changes to this accrual may be required in the future as additional information becomes available. INTELLECTUAL PROPERTY Certain subsidiaries of Johnson & Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products. Although these subsidiaries believe that they have substantial defenses to these challenges with respect to all material patents, there can be no assurance as to the outcome of these matters, and a loss in any of these cases could potentially adversely affect the ability of these subsidiaries to sell their products, or require the payment of past damages and future royalties. The most significant of these matters are described below. Medical Devices In January 2010, Tyco Healthcare Group, LP (Tyco) and U.S. Surgical Corporation (now Covidien plc) filed a lawsuit against Ethicon Endo-Surgery, Inc. (EES) in the United States District Court for the District of Connecticut alleging that EES's HARMONIC ® shears infringed three Tyco patents. The case was tried in July 2012, and in March 2013, the Court ruled that some of EES's HARMONIC ® shears infringed Tyco's patents and ordered EES to pay damages of approximately $176 million , but declined to order injunctive relief. EES appealed and in December 2014, the United States Court of Appeals for the Federal Circuit reversed the District Court's ruling and found all the asserted claims invalid. Tyco filed a motion for rehearing, which was denied in February 2015. In July 2015, Tyco filed a motion for review with the U.S. Supreme Court. In July 2014, Covidien filed another patent infringement lawsuit against EES in the United States District Court for the District of Connecticut seeking damages and a preliminary injunction, alleging that EES's newest version of its harmonic scalpels, the HARMONIC ACE ® + 7 Shears and the HARMONIC ACE ® + Shears, infringed the three Tyco patents asserted in the previous case. Covidien brought a motion for a preliminary injunction against the HARMONIC ACE ® +7 Shears, and in October 2014, the District Court granted Covidien's motion for a preliminary injunction. EES appealed and the Court of Appeals for the Federal Circuit granted EES an interim stay of the injunction, and then in March 2015, reversed the grant of the preliminary injunction. The claims asserted by Covidien in this case are the same claims that were declared invalid in December 2014 by the Court of Appeals in the Tyco case discussed above. In November 2007, Roche Diagnostics Operations, Inc., et al. (Roche) filed a patent infringement lawsuit against LifeScan, Inc. (LifeScan) in the United States District Court for the District of Delaware, alleging LifeScan's OneTouch ® Line of Blood Glucose Monitoring Systems infringe two patents related to the use of microelectrode sensors. Roche is seeking monetary damages and injunctive relief. In September 2009, LifeScan obtained a favorable ruling on claim construction that precluded a finding of infringement. Roche appealed and the Court of Appeals reversed the District Court's ruling on claim construction and remanded the case to the District Court for new findings on the issue. In December 2014, the District Court ruled in LifeScan's favor and reinstated the original claim construction. In February 2015, Roche appealed the ruling. In June 2009, Rembrandt Vision Technologies, L.P. (Rembrandt) filed a patent infringement lawsuit against Johnson & Johnson Vision Care, Inc. (JJVC) in the United States District Court for the Eastern District of Texas alleging that JJVC's manufacture and sale of its ACUVUE ® ADVANCE ® and ACUVUE ® OASYS ® Hydrogel Contact Lenses infringe their U.S. Patent No. 5,712,327 (the '327 patent). Rembrandt is seeking monetary relief. The case was transferred to the United States District Court for the Middle District of Florida. In May 2012, the jury returned a verdict holding that neither of the accused lenses infringes the '327 patent. Rembrandt appealed, and in August 2013, the United States Court of Appeals for the Federal Circuit affirmed the District Court's judgment. Rembrandt asked the District Court to grant it a new trial based on alleged new evidence, and in July 2014, the District Court denied Rembrandt’s motion. Rembrandt has appealed the District Court's denial of its motion for a new trial. In December 2009, the State of Israel filed a lawsuit in the District Court in Tel Aviv Jaffa against Omrix Biopharmaceuticals, Inc. and various affiliates (Omrix). In the lawsuit, the State claims that an employee of a government-owned hospital was the inventor on several patents related to fibrin glue technology that the employee developed while he was a government employee. The State claims that he had no right to transfer any intellectual property to Omrix because it belongs to the State. The State is seeking damages plus royalties on QUIXIL™ and EVICEL ® products, or alternatively, transfer of the patents to the State. The case remains active, but no trial date has been set. In September 2011, LifeScan, Inc. (LifeScan) filed a lawsuit against Shasta Technologies, LLC, Instacare Corp (now known as Pharmatech Solutions, Inc. (Pharmatech)) and Conductive Technologies, Inc. (collectively, Shasta) in the United States District Court for the Northern District of California for patent infringement for the making and marketing of a strip for use in LifeScan's OneTouch ® Blood Glucose Meters. Shasta has alleged that the three LifeScan patents-in-suit are invalid. Shasta also challenged the validity of the asserted patents in the United States Patent and Trademark Office (USPTO) and the patent infringement case has been stayed pending the outcome of the USPTO proceedings. The validity of two of the patents was confirmed by the USPTO and in August 2014, the USPTO determined that the third patent, U.S. Patent No. 7,250,105 (the '105 patent), is invalid. LifeScan is appealing that decision, and oral argument on the appeal is scheduled for December 2015. The patent case has resumed on the two other patents. In April 2013, Shasta brought counterclaims for alleged antitrust violations and false advertising and those claims have been stayed pending resolution of the patent infringement case. LifeScan entered into a settlement agreement with Shasta Technologies and Conductive Technologies and in March 2015, the Court entered a consent judgment against Shasta Technologies and Conductive Technologies. The litigation with Pharmatech continues. In May 2014, LifeScan filed a patent infringement lawsuit against UniStrip Technologies, LLC (UniStrip) in the United States District Court for the District of North Carolina alleging that the making and marketing of Unistrip’s strips infringe the same patents asserted against Shasta above. That case has been stayed pending the outcome of the appeal of the USPTO's decision on the validity of the '105 patent. In July 2014, UniStrip brought a lawsuit against LifeScan in the United States District Court for the Eastern District of Pennsylvania, alleging antitrust violations relating to marketing practices for LifeScan's strips. In September 2012, Bonutti Skeletal Innovations LLC (Bonutti), a non-practicing entity, filed a patent infringement lawsuit against DePuy Mitek, LLC, The DePuy Institute, LLC (now DePuy Synthes Institute, LLC), DePuy, Inc. (now DePuy Synthes, Inc.) and DePuy Orthopaedics, Inc. (collectively, DePuy) in the United States District Court for the District of Massachusetts, alleging that DePuy’s manufacture, sale and/or method of using the SIGMA ® Family of Partial and Total Knee Systems and the LCS ® COMPLETE™ Knee System willfully infringe three of Bonutti’s patents. Bonutti also alleges that the method of using certain of DePuy’s suture anchors willfully infringe four of Bonutti’s other patents. In August 2014, the parties entered into a settlement of the portion of the lawsuit relating to suture anchors, and in March 2015, the parties entered into a settlement agreement relating to the remaining portion of the case. In March 2013, Medinol Ltd. (Medinol) filed a patent infringement lawsuit against Cordis Corporation (Cordis) and Johnson & Johnson in the United States District Court for the Southern District of New York alleging that all of Cordis's sales of the CYPHER ® and CYPHER SELECT™ Stents made in the United States since 2005 willfully infringed four of Medinol's patents directed to the geometry of articulated stents. Medinol is seeking damages and attorney's fees. After trial in January 2014, the District Court dismissed the case, finding Medinol unreasonably delayed bringing its claims, and Medinol did not appeal the decision. In September 2014, the District Court denied a motion by Medinol to vacate the judgment and grant it a new trial. Medinol is appealing this decision. Following the divestiture of Cordis, the Company retains any liability that may result from this case. In January 2014, Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare S.A. (collectively, Baxter) filed a lawsuit against Johnson & Johnson, Ethicon, Inc. (Ethicon), Ferrosan Medical Devices A/S and Packaging Coordinators Inc. in the United States District Court for the Northern District of Illinois, alleging that the manufacture, importation, sale and/or use of Ethicon’s SURGIFLO ® Hemostatic Matrix Family of Products infringes six of Baxter’s patents. Baxter is seeking monetary damages and injunctive relief. In February 2014, Baxter also filed a complaint before the United States International Trade Commission (ITC) against the same defendants alleging that the importation into the United States of Ethicon’s SURGIFLO ® Hemostatic Matrix Family of Products violates Section 337 of the Tariff Act of 1930 due to the alleged infringement of four of its products, and is seeking an exclusion order to enjoin the importation into the United States of such products. The ITC case was tried in January 2015 and in March 2015, the parties entered into an agreement settling the ITC and District Court cases. In June 2014, My Health, Inc. (My Health) filed a patent infringement lawsuit against LifeScan, Inc. (LifeScan) in the United States District Court for the Eastern District of Texas, alleging LifeScan's OneTouch ® Verio ® IQ Blood Glucose Monitoring System infringes My Health's patent related to a method for monitoring and treating patients. My Health sought monetary damages and injunctive relief. In October 2014, Lifescan filed an Inter Partes review proceeding in the United States Patent and Trademark Office seeking to invalidate My Health’s patent. In December 2014, LifeScan moved to stay the lawsuit pending a decision in the Inter Partes review proceeding. In May 2015, LifeScan and My Health entered into a settlement agreement and LifeScan terminated its petition for Inter Partes Review. In December 2014, Bonutti Skeletal Innovations LLC (Bonutti) sued DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. in the United States District Court for the District of Massachusetts, alleging that DePuy Synthes's product line of spine implants infringes six patents owned by Bonutti, generally covering wedge implants and their methods of implantation. Bonutti is seeking monetary damages and injunctive relief. Pharmaceutical In 2012 and 2013, Noramco, Inc. (Noramco) moved to intervene in several patent infringement lawsuits filed in the United States District Court for the Southern District of New York by Purdue Pharma L.P. and others (Purdue) against Noramco oxycodone customers, Impax Laboratories, Inc. (Impax), Teva Pharmaceuticals USA, Inc. (Teva), Amneal Pharmaceuticals, LLC (Amneal), Watson Laboratories, Inc.- Florida (Watson) and Andrx Labs, LLC (Andrx). The lawsuits are in response to the defendants' respective Abbreviated New Drug Applications seeking approval to market generic extended release oxycodone products before the expiration of certain Purdue patents. Three of the asserted patents relate to oxycodone and processes for making oxycodone, and Noramco has agreed to defend the lawsuits on behalf of Impax, Teva, Amneal, Watson, and Andrx. In April 2013, Watson and Andrx entered into a settlement with Purdue. The trial against Impax and Teva (and others) took place in September 2013, and Noramco defended Teva and Impax. In November 2013, Impax entered into a settlement with Purdue. In January 2014, the Court issued a decision invalidating the relevant Purdue patents and, based on that decision, subsequently dismissed the lawsuit against Amneal (and other parties not defended by Noramco). Purdue has appealed the Court's decision. If Purdue prevails in its appeal of the invalidity decision, it can reinstitute its action against Amneal. In December 2014, Teva entered into a confidential settlement with Purdue, and Teva subsequently moved to have the appeal dismissed as moot in view of the settlement. The Federal Circuit deferred judgment on Teva’s motion to dismiss, and oral argument on Purdue’s appeal is set for November 2015. Johnson & Johnson acquired the prostate cancer business of Aragon Pharmaceuticals, Inc. (Aragon), including ARN-509, a compound being tested for treatment of prostate cancer, in September 2013. Prior to the acquisition, in May 2011, Medivation, Inc. (Medivation) had sued Aragon and the University of California seeking rights to ARN-509. In December 2012, the State Court granted summary judgment to Aragon on Medivation's claims, awarding the rights of the ARN-509 compound to Aragon, and in January 2013, the Court dismissed the case against Aragon. Medivation has appealed. REMICADE ® Related Cases In March 2013, Hospira Healthcare Corporation (Hospira) filed an impeachment proceeding against The Kennedy Institute of Rheumatology (Kennedy) challenging the validity of a Canadian patent related to REMICADE ® (a Feldman patent), which is exclusively licensed to Janssen Biotech, Inc. (JBI). In October 2013, Kennedy, along with JBI, Janssen Inc. and Cilag GmbH International (both affiliates of JBI), filed a counterclaim for infringement against Celltrion Healthcare Co., Ltd., Celltrion Inc. (together, Celltrion) and Hospira. The counterclaim alleges that the products described in Celltrion’s and Hospira’s marketing applications to Health Canada for their subsequent entry biologics (SEB) to REMICADE ® would infringe the Feldman patents owned by Kennedy. Discovery in the patent action is ongoing. Trial has been scheduled for September 2016. In January 2014, Health Canada approved Celltrion’s SEB to REMICADE ® , allowing Celltrion to market its biosimilar version of REMICADE ® in Canada, regardless of the pending patent action. In June 2014, Hospira received approval for its SEB to REMICADE ® . In July 2014, Janssen Inc. (Janssen) filed a lawsuit to compel the Canadian Minister of Health to withdraw the Notice of Compliance for Hospira’s SEB because Hospira did not serve a Notice of Allegation on Janssen to address the patent listed by Janssen on the Patent Register. In March 2015, the parties entered into a settlement agreement whereby Health Canada agreed to a Consent Judgment setting aside Hospira’s Notice of Compliance, subject to Health Canada's right to appeal, which appeal was filed in June 2015. Nevertheless, Hospira began marketing a biosimilar version of REMICADE ® as a distributor under Celltrion's Notice of Compliance. In September 2013, JBI and NYU Langone Medical Center (NYU Medical Center) received an Office Action from the United States Patent and Trademark Office (USPTO) rejecting the claims in U.S. Patent No. 6,284,471 relating to REMICADE ® (the '471 patent) in a reexamination proceeding instituted by a third party. The '471 patent is co-owned by JBI and NYU Medical Center, and NYU Medical Center granted JBI an exclusive license to NYU Medical Center's rights under the patent. Currently, the '471 patent in the United States expires in September 2018. JBI responded to that rejection in December 2013 and in August 2014, JBI and NYU Medical Center received a further rejection. JBI responded to the rejection by filing a further amendment and in November 2014, JBI's petition to enter the amendment was granted. The application was returned to the examiner for issuance of a new Office Action, which occurred in February 2015, further rejecting the patent. JBI responded to that rejection and in April 2015, the USPTO issued a further action maintaining its rejection of the '471 patent. In May 2015, JBI filed a notice of appeal to the USPTO's Patent Trial and Appeal Board, and the appeal is currently pending. The '471 patent remains a valid and enforceable patent as it undergoes reexamination at the USPTO. JBI will continue to defend the patent and, if necessary, will pursue all available appeals. In August 2014, Celltrion filed for FDA approval to make and sell its own biosimilar version of REMICADE ® . In February 2015, JBI received a Notice of Commercial Marketing from Celltrion purportedly in accordance with the Biologics Price Competition and Innovation Act (the BPCIA), notifying JBI that Celltrion and/or Hospira intended to begin commercial marketing of a biosimilar product as early as 180 days from the date of the notice. In March 2015, JBI filed a lawsuit in the United States District Court for the District of Massachusetts against Celltrion and Hospira seeking a declaratory judgment that their biosimilar product for which they are seeking FDA approval under the new BPCIA statute infringes or potentially infringes six JBI patents. JBI is also seeking a declaratory judgment that defendants have failed to comply with certain procedural requirements of the BPCIA. In addition, JBI has moved for a preliminary and permanent injunction to prohibit Celltrion and Hospira from launching their biosimilar product until 180 days after they have given JBI a Notice of Commercial Marketing. Subsequently in March 2015, JBI moved to stay all proceedings in the District Court with respect to the ‘471 patent, pending the USPTO re-examination proceeding. If any of the REMICADE ® related patents discussed above is found to be invalid, any such patent could not be relied upon to prevent the introduction of biosimilar versions of REMICADE ® . Biosimilar versions of REMICADE ® have been introduced in certain markets outside the United States, resulting in a reduction in sales of REMICADE ® in those markets. The timing of the possible introduction of a biosimilar version of REMICADE ® in the United States would be subject to approval by the FDA. Loss of exclusivity will likely result in a further reduction in sales as additional biosimilar versions of REMICADE ® are introduced to the market. Litigation Against Filers of Abbreviated New Drug Applications (ANDAs) The following summarizes lawsuits pending against generic companies that have filed Abbreviated New Drug Applications (ANDAs) with the FDA, or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson & Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement, invalidity and unenforceability of the applicable patents. In the event the subsidiaries are not successful in these actions, or the statutory 30-month stays of the ANDAs expire before the United States District Court rulings are obtained, the third-party companies involved will have the ability, upon approval of the FDA, to introduce generic versions of the products at issue to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. PREZISTA ® A number of generic companies have filed ANDAs seeking approval to market generic versions of PREZISTA ® . In November 2010, Tibotec, Inc. (now Tibotec, LLC) and Tibotec Pharmaceuticals (now Janssen R&D Ireland) (collectively, Tibotec) filed a patent infringement lawsuit against Lupin, Ltd., Lupin Pharmaceuticals, Inc. (collectively, Lupin), Mylan, Inc. and Mylan Pharmaceuticals, Inc. (collectively, Mylan) in the United States District Court for the District of New Jersey in response to Lupin's and Mylan's respective ANDAs seeking approval to market generic versions of Tibotec's PREZISTA ® product before the expiration of Tibotec's patent relating to PREZISTA ® . Lupin and Mylan each filed counterclaims alleging non-infringement and invalidity. In July 2011, Tibotec filed another patent infringement lawsuit against Lupin in the United States District Court for the District of New Jersey in response to Lupin's supplement to its ANDA to add new dosage strengths for its proposed product. In August 2011, Tibotec and G.D. Searle & Company (G.D. Searle) filed a patent infringement lawsuit against Lupin and Mylan in response to their notice letters advising that their ANDAs are seeking approval to market generic versions of Tibotec's PREZISTA ® product before the expiration of two additional patents relating to PREZISTA ® that Tibotec exclusively licenses from G.D. Searle. In September 2011, the Court consolidated the above lawsuits (referred to here as the First Consolidated Action). The approved New Drug Application for PREZISTA ® was transferred from Tibotec, Inc. to Janssen Products, LP in December 2011. In 2012 and 2013, Janssen Products, LP and Janssen R&D Ireland (collectively, Janssen) added several patents that they own or exclusively license from G.D. Searle to the First Consolidated Action against Mylan and Lupin. In June 2013, Janssen and G.D. Searle dismissed their claims relating to the patents owned by G.D. Searle against Lupin and Mylan, based on those parties’ agreement not to seek FDA approval of their respective ANDAs until the November 2017 expiration of the G.D. Searle patents. After a trial regarding the remaining patents in the First Consolidated Action, the Court issued a decision in August 2014 in favor of Janssen, holding that the asserted patents are valid and would be infringed by Lupin's and Mylan's marketing of their proposed products. Mylan and Lupin filed an appeal. In May 2013, Lupin notified Janssen that it filed an ANDA seeking approval to market a new dosage strength of its generic version of PREZISTA ® . In response, Janssen filed a patent infringement lawsuit in the United States District Court for the District of New Jersey, alleging that Lupin's new dosage strength would infringe the same patents that Janssen is asserting against Lupin in the original action. In March 2014, Janssen filed a patent infringement lawsuit against Lupin in the United States District Court for the District of New Jersey, alleging infringement of United States Patent No 8,518,987 (the ‘987 patent). In January 2015, the Court consolidated these lawsuits (referred to here as the Second Consolidated Action), and stayed them pending Lupin's appeal of the Court's decision in the First Consolidated Action. In April 2015, Lupin filed an Inter Partes Review in the USPTO seeking to invalidate the ‘987 patent and in October 2015, the USPTO denied Lupin's petition. Janssen filed a patent infringement lawsuit agai

Fair Value Measurements (Polici

Fair Value Measurements (Policies)	9 Months Ended
	Sep. 27, 2015
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents, Policy [Policy Text Block]	The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available for current operations and are classified as current marketable securities.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 27, 2015
Inventory Disclosure [Abstract]
Summary of Inventories	(Dollars in Millions) September 27, 2015 December 28, 2014 Raw materials and supplies $ 1,198 1,214 Goods in process 2,026 2,461 Finished goods 4,982 4,509 Total inventories $ 8,206 8,184

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Sep. 27, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets and Goodwill	(Dollars in Millions) September 27, 2015 December 28, 2014 Intangible assets with definite lives: Patents and trademarks — gross $ 8,298 9,074 Less accumulated amortization 4,687 4,700 Patents and trademarks — net 3,611 4,374 Customer relationships and other intangibles — gross 17,739 17,970 Less accumulated amortization 5,637 5,227 Customer relationships and other intangibles — net 12,102 12,743 Intangible assets with indefinite lives: Trademarks 7,084 7,263 Purchased in-process research and development 3,191 2,842 Total intangible assets with indefinite lives 10,275 10,105 Total intangible assets — net $ 25,988 27,222
Goodwill	Goodwill as of September 27, 2015 was allocated by segment of business as follows: (Dollars in Millions) Consumer Pharm Med Devices Total Goodwill, net at December 28, 2014 $ 7,675 2,626 11,531 21,832 Goodwill, related to acquisitions — 64 22 86 Goodwill, related to divestitures (117 ) (17 ) (1 ) (135 ) Currency translation/Other (350 ) (56 ) (98 ) (1) (504 ) Goodwill, net as of September 27, 2015 $ 7,208 2,617 11,454 21,279 See Note 10 to the Consolidated Financial Statements for more details related to business combinations and divestitures. (1) Includes $98 million classified as held for sale, a component of other assets on the Consolidated Balance Sheet, related to the divestiture of Cordis which was pending as of September 27, 2015.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 27, 2015
Fair Value Disclosures [Abstract]
Marketable Securities	The Company's cash, cash equivalents and current marketable securities as of September 27, 2015 comprised: September 27, 2015 (Dollars in Millions) Carrying Amount Unrealized Gain Unrealized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 1,976 — — 1,976 1,976 U.S. Gov't Securities (1) 15,694 5 — 15,699 1,700 13,994 Other Sovereign Securities (1) 2,737 — — 2,737 1,192 1,545 U.S. Reverse repurchase agreements (1) 3,015 — — 3,015 3,015 Other Reverse repurchase agreements (1) 2,179 — — 2,179 2,179 Corporate debt securities (1) 4,237 — — 4,237 1,378 2,859 Money market funds 1,358 — — 1,358 1,358 Time deposits (1) 841 — — 841 841 Subtotal 32,037 5 — 32,042 13,639 18,398 Gov't Securities 4,255 14 (1 ) 4,268 — 4,268 Corporate debt securities 1,002 2 (3 ) 1,001 — 1,001 Subtotal Available for Sale (2) $ 5,257 16 (4 ) 5,269 — 5,269 Total cash, cash equivalents and current marketable securities 13,639 23,667 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Summary of designated derivatives	The following table is a summary of the activity related to derivatives designated as cash flow hedges for the fiscal third quarters in 2015 and 2014 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal Third Quarters Ended Cash Flow Hedges By Income Statement Caption September 27, 2015 September 28, 2014 September 27, 2015 September 28, 2014 September 27, 2015 September 28, 2014 Sales to customers (3) $ 3 (43 ) (24 ) (2 ) (3 ) — Cost of products sold (3) 222 (37 ) (34 ) 37 1 (2 ) Research and development expense (3) (10 ) 25 7 8 — — Interest (income)/Interest expense, net (4) (13 ) 11 1 (6 ) — — Other (income) expense, net (3) (42 ) 58 12 12 (1 ) — Total $ 160 14 (38 ) 49 (3 ) (2 ) The following table is a summary of the activity related to derivatives designated as cash flow hedges for the first fiscal nine months in 2015 and 2014 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal Nine Months Ended Cash Flow Hedges By Income Statement Caption September 27, 2015 September 28, 2014 September 27, 2015 September 28, 2014 September 27, 2015 September 28, 2014 Sales to customers (3) $ (52 ) (73 ) (95 ) 6 (5 ) 1 Cost of products sold (3) 106 (187 ) 82 196 15 (4 ) Research and development expense (3) (13 ) 28 (2 ) (5 ) — (1 ) Interest (income)/Interest expense, net (4) (42 ) 21 (2 ) (12 ) — — Other (income) expense, net (3) 27 72 54 (9 ) — — Total $ 26 (139 ) 37 176 10 (4 ) All amounts shown in the table above are net of tax. (1) Effective portion (2) Ineffective portion (3) Forward foreign exchange contracts (4) Cross currency interest rate swaps
Financial assets and liabilities at fair value	The Company’s significant financial assets and liabilities measured at fair value as of September 27, 2015 and December 28, 2014 were as follows: September 27, 2015 December 28, 2014 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts (7) $ — 791 — 791 996 Interest rate contracts (2)(4)(7) — 51 — 51 31 Total — 842 — 842 1,027 Liabilities: Forward foreign exchange contracts (8) — 472 — 472 751 Interest rate contracts (3)(4) — 185 — 185 8 Total — 657 — 657 759 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts (7) — 56 — 56 29 Liabilities: Forward foreign exchange contracts (8) — 39 — 39 51 Available For Sale Other Investments: Equity investments (5) 1,130 — — 1,130 679 Debt securities (6) $ — 5,269 — 5,269 — (1) 2014 assets and liabilities are all classified as Level 2 with the exception of equity investments of $679 million , which are classified as Level 1. (2) Includes $45 million and $29 million of non-current other assets for September 27, 2015 and December 28, 2014, respectively. (3) Includes $185 million and $8 million of non-current other liabilities for September 27, 2015 and December 28, 2014, respectively. (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets. The carrying amount of the equity investments were $531 million and $284 million as of September 27, 2015 and December 28, 2014, respectively. The unrealized gains were $648 million and $406 million as of September 27, 2015 and December 28, 2014, respectively. The unrealized losses were $49 million and $11 million as of September 27, 2015 and December 28, 2014, respectively. (6) Classified as current marketable securities. (7) Classified as other current assets. (8) Classified as accounts payable
Financial assets and liabilities not measured at fair value	Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of September 27, 2015 : (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 5,677 5,677 Non-Current Debt 3 month LIBOR+0.07% FRN due 2016 800 800 0.70% Notes due 2016 399 400 5.55% Debentures due 2017 1,000 1,084 1.125% Notes due 2017 706 710 5.15% Debentures due 2018 899 995 1.65% Notes due 2018 609 616 4.75% Notes due 2019 (1B Euro 1.1267) 1,123 1,322 1.875% Notes due 2019 510 517 3% Zero Coupon Convertible Subordinated Debentures due in 2020 140 181 2.95% Debentures due 2020 545 585 3.55% Notes due 2021 448 487 2.45% Notes due 2021 350 357 6.73% Debentures due 2023 250 326 3.375% Notes due 2023 811 856 5.50% Notes due 2024 (500 MM GBP 1.5215) 756 940 6.95% Notes due 2029 297 426 4.95% Debentures due 2033 500 571 4.375% Notes due 2033 864 932 5.95% Notes due 2037 996 1,275 5.85% Debentures due 2038 700 898 4.50% Debentures due 2040 541 585 4.85% Notes due 2041 298 345 4.50% Notes due 2043 499 539 Other 32 32 Total Non-Current Debt $ 14,073 15,779

Pensions and Other Postretire23

Pensions and Other Postretirement Benefits (Tables)	9 Months Ended
	Sep. 27, 2015
Compensation and Retirement Disclosure [Abstract]
Components of net periodic benefit cost	Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the fiscal third quarters of 2015 and 2014 include the following components: Fiscal Third Quarters Ended Retirement Plans Other Benefit Plans (Dollars in Millions) September 27, 2015 September 28, 2014 September 27, 2015 September 28, 2014 Service cost $ 247 197 64 52 Interest cost 246 255 46 50 Expected return on plan assets (451 ) (403 ) (2 ) (2 ) Amortization of prior service cost/(credit) — 1 (8 ) (8 ) Recognized actuarial losses 186 115 50 33 Curtailments and settlements — (11 ) — — Net periodic benefit cost $ 228 154 150 125 Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the fiscal nine months of 2015 and 2014 include the following components: Fiscal Nine Months Ended Retirement Plans Other Benefit Plans (Dollars in Millions) September 27, 2015 September 28, 2014 September 27, 2015 September 28, 2014 Service cost $ 744 594 193 158 Interest cost 743 768 139 149 Expected return on plan assets (1,361 ) (1,212 ) (5 ) (5 ) Amortization of prior service cost/(credit) 1 4 (25 ) (25 ) Recognized actuarial losses 560 346 150 101 Curtailments and settlements 4 (11 ) — — Net periodic benefit cost $ 691 489 452 378

Accumulated Other Comprehensi24

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 27, 2015
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) December 28, 2014 $ (4,803 ) 257 (6,317 ) 141 (10,722 ) Net change (2,729 ) 140 461 (11 ) (2,139 ) September 27, 2015 $ (7,532 ) 397 (5,856 ) 130 (12,861 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 27, 2015
Earnings Per Share [Abstract]
Reconciliation of basic net earnings per share to diluted net earnings per share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal third quarters ended September 27, 2015 and September 28, 2014 : Fiscal Third Quarters Ended (Shares in Millions) September 27, 2015 September 28, 2014 Basic net earnings per share $ 1.21 1.69 Average shares outstanding — basic 2,768.4 2,814.4 Potential shares exercisable under stock option plans 129.4 148.4 Less: shares which could be repurchased under treasury stock method (92.8 ) (101.2 ) Convertible debt shares 2.2 2.7 Average shares outstanding — diluted 2,807.2 2,864.3 Diluted earnings per share $ 1.20 1.66 The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal nine months ended September 27, 2015 and September 28, 2014 : Fiscal Nine Months Ended (Shares in Millions) September 27, 2015 September 28, 2014 Basic net earnings per share $ 4.39 4.89 Average shares outstanding — basic 2,774.8 2,822.0 Potential shares exercisable under stock option plans 129.1 148.8 Less: shares which could be repurchased under treasury stock method (89.0 ) (102.3 ) Convertible debt shares 2.2 2.7 Average shares outstanding — diluted 2,817.1 2,871.2 Diluted earnings per share $ 4.33 4.81

Segments of Business and Geog26

Segments of Business and Geographic Areas (Tables)	9 Months Ended
	Sep. 27, 2015
Segment Reporting [Abstract]
Sales By Segment Of Business	Fiscal Third Quarters Ended (Dollars in Millions) September 27, September 28, Percent Change Consumer United States $ 1,277 1,173 8.9 % International 2,037 2,416 (15.7 ) Total 3,314 3,589 (7.7 ) Pharmaceutical United States 4,509 4,723 (4.5 ) International 3,185 3,584 (11.1 ) Total 7,694 8,307 (7.4 ) Medical Devices United States 3,005 2,946 2.0 International 3,089 3,625 (14.8 ) Total 6,094 6,571 (7.3 ) Worldwide United States 8,791 8,842 (0.6 ) International 8,311 9,625 (13.7 ) Total $ 17,102 18,467 (7.4 )% Fiscal Nine Months Ended (Dollars in Millions) September 27, September 28, Percent Change Consumer United States $ 3,991 3,802 5.0 % International 6,196 7,088 (12.6 ) Total 10,187 10,890 (6.5 ) Pharmaceutical United States 13,423 13,076 2.7 International 9,943 11,238 (11.5 ) Total 23,366 24,314 (3.9 ) Medical Devices United States 8,980 9,300 (3.4 ) International 9,730 11,573 (15.9 ) Total 18,710 20,873 (10.4 ) Worldwide United States 26,394 26,178 0.8 International 25,869 29,899 (13.5 ) Total $ 52,263 56,077 (6.8 )%
Operating profit by segment of business	Fiscal Third Quarters Ended (Dollars in Millions) September 27, September 28, Percent Change Consumer (1) $ 811 407 99.3 % Pharmaceutical (2) 2,732 3,247 (15.9 ) Medical Devices (3) 835 3,399 (75.4 ) Segments operating profit 4,378 7,053 (37.9 ) Less: Expense not allocated to segments (4) 256 243 Worldwide income before taxes $ 4,122 6,810 (39.5 )% Fiscal Nine Months Ended (Dollars in Millions) September 27, 2015 September 28, 2014 Percent Change Consumer (1) $ 1,772 1,588 11.6 % Pharmaceutical (2) 9,816 9,921 (1.1 ) Medical Devices (3) 4,640 7,069 (34.4 ) Segments operating profit 16,228 18,578 (12.6 ) Less: Expense not allocated to segments (4) 790 718 Worldwide income before taxes $ 15,438 17,860 (13.6 )% (1) Includes a gain of $229 million from the divestiture of the SPLENDA ® brand recorded in the fiscal third quarter and fiscal nine months of 2015. Includes a gain of $388 million from the divestiture of the K-Y ® brand recorded in the fiscal nine months of 2014. (2) Includes litigation expense of $136 million in the fiscal nine months of 2015. Includes a gain of $981 million recorded in the fiscal nine months of 2015 from the divestiture of the U.S. license rights to NUCYNTA ® (tapentadol), NUCYNTA ® ER (tapentadol extended-release tablets), and NUCYNTA ® (tapentadol) oral solution. Includes an additional year of the Branded Prescription Drug Fee of $220 million recorded in the fiscal third quarter and fiscal nine months of 2014. (3) Includes litigation expense of $409 million related to product liability and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal third quarter of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $225 million , Synthes integration costs of $167 million and $126 million for costs associated with the DePuy ASR TM Hip program recorded in the fiscal third quarter of 2014. Includes $148 million for costs associated with the DePuy ASR TM Hip program, Synthes integration costs of $113 million and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal nine months of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $501 million , Synthes integration costs of $429 million and $126 million for costs associated with the DePuy ASR TM Hip program recorded in the fiscal nine months of 2014. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	Fiscal Third Quarters Ended (Dollars in Millions) September 27, 2015 September 28, 2014 Percent Change United States $ 8,791 8,842 (0.6 )% Europe 3,802 4,446 (14.5 ) Western Hemisphere, excluding U.S. 1,463 1,820 (19.6 ) Asia-Pacific, Africa 3,046 3,359 (9.3 ) Total $ 17,102 18,467 (7.4 )% Fiscal Nine Months Ended (Dollars in Millions) September 27, 2015 September 28, 2014 Percent Change United States $ 26,394 26,178 0.8 % Europe 11,993 14,387 (16.6 ) Western Hemisphere, excluding U.S. 4,603 5,378 (14.4 ) Asia-Pacific, Africa 9,273 10,134 (8.5 ) Total $ 52,263 56,077 (6.8 )%

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Sep. 27, 2015	Dec. 28, 2014
Summary of Inventories
Raw materials and supplies	$ 1,198	$ 1,214
Goods in process	2,026	2,461
Finished goods	4,982	4,509
Total inventories	$ 8,206	$ 8,184

Intangible Assets and Goodwil28

Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	Sep. 27, 2015	Dec. 28, 2014
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	$ 10,275	$ 10,105
Total intangible assets - net	25,988	27,222
Trademarks
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	7,084	7,263
Purchased In-Process Research And Development
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	3,191	2,842
Patents And Trademarks
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	8,298	9,074
Less accumulated amortization	4,687	4,700
Finite-Lived Intangible Assets, Net	3,611	4,374
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	17,739	17,970
Less accumulated amortization	5,637	5,227
Finite-Lived Intangible Assets, Net	$ 12,102	$ 12,743

Goodwill By Segment (Details)

Goodwill By Segment (Details) $ in Millions	9 Months Ended
	Sep. 27, 2015USD ($)
Goodwill [Roll Forward]
Goodwill Beginning of Period	$ 21,832
Goodwill, related to acquisitions	86
Goodwill, related to divestitures	(135)
Currency translation/Other	(504)
Goodwill End of Period	21,279
Consumer
Goodwill [Roll Forward]
Goodwill Beginning of Period	7,675
Goodwill, related to acquisitions	0
Goodwill, related to divestitures	(117)
Currency translation/Other	(350)
Goodwill End of Period	7,208
Pharmaceutical
Goodwill [Roll Forward]
Goodwill Beginning of Period	2,626
Goodwill, related to acquisitions	64
Goodwill, related to divestitures	(17)
Currency translation/Other	(56)
Goodwill End of Period	2,617
Medical Devices
Goodwill [Roll Forward]
Goodwill Beginning of Period	11,531
Goodwill, related to acquisitions	22
Goodwill, related to divestitures	(1)
Currency translation/Other	(98)	[1]
Goodwill End of Period	11,454
Cordis | Goodwill
Goodwill [Line Items]
Assets Held-for-sale, Other, Noncurrent	$ 98
[1]	)Includes $98 million classified as held for sale, a component of other assets on the Consolidated Balance Sheet, related to the divestiture of Cordis which was pending as of September 27, 2015.

Intangible Assets and Goodwil30

Intangible Assets and Goodwill (Details Textuals) - USD ($) $ in Millions	9 Months Ended
	Sep. 27, 2015	Sep. 28, 2014
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 1,200
Intangible Assets and Goodwill (Textuals)
Amortization expense of amortizable intangible assets	912	$ 1,033
Finite-Lived Intangible Assets, Amortization Expense, Year Two	1,200
Finite-Lived Intangible Assets, Amortization Expense, Year Three	1,200
Finite-Lived Intangible Assets, Amortization Expense, Year Four	1,200
Finite-Lived Intangible Assets, Amortization Expense, Year Five	$ 1,200
Patents And Trademarks
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life	17 years
Customer relationships and other intangible assets
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life	24 years

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Designated as Hedging Instrument - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 27, 2015	Sep. 28, 2014	Sep. 27, 2015	Sep. 28, 2014
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1]	$ 160	$ 14	$ 26	$ (139)
Gain/ (Loss) reclassified from Accumulated OCI into income	[1]	(38)	49	37	176
Gain/ (Loss) recognized in Other income/expense	[2]	(3)	(2)	10	(4)
Foreign exchange contracts | Sales to customers
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1],[3]	3	(43)	(52)	(73)
Gain/ (Loss) reclassified from Accumulated OCI into income	[1],[3]	(24)	(2)	(95)	6
Gain/ (Loss) recognized in Other income/expense	[2],[3]	(3)	0	(5)	1
Foreign exchange contracts | Cost of products sold
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1],[3]	222	(37)	106	(187)
Gain/ (Loss) reclassified from Accumulated OCI into income	[1],[3]	(34)	37	82	196
Gain/ (Loss) recognized in Other income/expense	[2],[3]	1	(2)	15	(4)
Foreign exchange contracts | Research and development expense
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1],[3]	(10)	25	(13)	28
Gain/ (Loss) reclassified from Accumulated OCI into income	[1],[3]	7	8	(2)	(5)
Gain/ (Loss) recognized in Other income/expense	[2],[3]	0	0	0	(1)
Foreign exchange contracts | Other (income) expense, net
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1],[3]	(42)	58	27	72
Gain/ (Loss) reclassified from Accumulated OCI into income	[1],[3]	12	12	54	(9)
Gain/ (Loss) recognized in Other income/expense	[2],[3]	(1)	0	0	0
Cross currency interest rate swaps | Interest (income)/Interest expense, net
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1],[4]	(13)	11	(42)	21
Gain/ (Loss) reclassified from Accumulated OCI into income	[1],[4]	1	(6)	(2)	(12)
Gain/ (Loss) recognized in Other income/expense	[2],[4]	$ 0	$ 0	$ 0	$ 0
[1]	Effective portion
[2]	Ineffective portion
[3]	Forward foreign exchange contracts
[4]	Cross currency interest rate swaps

Fair Value Measurements (Deta32

Fair Value Measurements (Details 1) - USD ($) $ in Millions		Sep. 27, 2015	Dec. 28, 2014
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets		$ 842
Derivatives designated as hedging instruments : Liabilities		657
Available-for-sale Securities	[1]	5,269
Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets		0
Derivatives designated as hedging instruments : Liabilities		0
Available-for-sale Securities, Equity Securities	[2]	1,130	$ 679	[3]
Available-for-sale Securities	[1]	0
Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets		842	1,027	[3]
Derivatives designated as hedging instruments : Liabilities		657	759	[3]
Available-for-sale Securities, Equity Securities	[2]	0
Available-for-sale Securities	[1]	5,269	0	[3]
Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets		0
Derivatives designated as hedging instruments : Liabilities		0
Available-for-sale Securities, Equity Securities	[2]	0
Available-for-sale Securities	[1]	0
Interest Rate Contract
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4],[5],[6]	51
Derivatives designated as hedging instruments : Liabilities	[6],[7]	185
Derivative Assets, Noncurrent		45	29
Derivative Liabilities, Noncurrent		185	8
Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4],[5],[6]	0
Derivatives designated as hedging instruments : Liabilities	[6],[7]	0
Interest Rate Contract | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4],[5],[6]	51	31	[3]
Derivatives designated as hedging instruments : Liabilities	[6],[7]	185	8	[3]
Interest Rate Contract | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4],[5],[6]	0
Derivatives designated as hedging instruments : Liabilities	[6],[7]	0
Foreign exchange contracts
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4]	791
Derivatives designated as hedging instruments : Liabilities	[8]	472
Derivatives not designated as hedging instruments : Assets	[4]	56
Derivatives not designated as hedging instruments : Liabilities	[8]	39
Foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4]	0
Derivatives designated as hedging instruments : Liabilities	[8]	0
Derivatives not designated as hedging instruments : Assets	[4]	0
Derivatives not designated as hedging instruments : Liabilities	[8]	0
Foreign exchange contracts | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4]	791	996	[3]
Derivatives designated as hedging instruments : Liabilities	[8]	472	751	[3]
Derivatives not designated as hedging instruments : Assets	[4]	56	29	[3]
Derivatives not designated as hedging instruments : Liabilities	[8]	39	51	[3]
Foreign exchange contracts | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4]	0
Derivatives designated as hedging instruments : Liabilities	[8]	0
Derivatives not designated as hedging instruments : Assets	[4]	0
Derivatives not designated as hedging instruments : Liabilities	[8]	0
Equity Securities [Member]
Financial assets and liabilities at fair value
Available-for-sale Securities, Equity Securities		531	284
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		648	406
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		$ 49	$ 11
[1]	Classified as current marketable securities
[2]	Classified as non-current other assets. The carrying amount of the equity investments were $531 million and $284 million as of September 27, 2015 and December 28, 2014, respectively. The unrealized gains were $648 million and $406 million as of September 27, 2015 and December 28, 2014, respectively. The unrealized losses were $49 million and $11 million as of September 27, 2015 and December 28, 2014, respectively
[3]	2014 assets and liabilities are all classified as Level 2 with the exception of equity investments of $679 million, which are classified as Level 1.
[4]	Classified as other current assets
[5]	Includes $45 million and $29 million of non-current other assets for September 27, 2015 and December 28, 2014, respectively.
[6]	Includes cross currency interest rate swaps and interest rate swaps.
[7]	Includes $185 million and $8 million of non-current other liabilities for September 27, 2015 and December 28, 2014, respectively.
[8]	Classified as accounts payable.

Fair Value Measurements (Deta33

Fair Value Measurements (Details 2) (Details) - USD ($) $ in Millions	Sep. 27, 2015	Dec. 28, 2014
Financial Liabilities
Current Debt	$ 5,677	$ 3,638
Non-Current Debt
Non-Current Debt	14,073	$ 15,122
Carrying Amount
Financial Liabilities
Current Debt	5,677
Non-Current Debt
Non-Current Debt	14,073
Estimate of Fair Value, Fair Value Disclosure
Financial Liabilities
Current Debt	5,677
Non-Current Debt
Non-Current Debt	15,779
3 month LIBOR0.07% FRN due 2016 | Carrying Amount
Non-Current Debt
Non-Current Debt	800
3 month LIBOR0.07% FRN due 2016 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	800
0.70% Notes due 2016 | Carrying Amount
Non-Current Debt
Non-Current Debt	399
0.70% Notes due 2016 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	400
5.55% Debentures due 2017 | Carrying Amount
Non-Current Debt
Non-Current Debt	1,000
5.55% Debentures due 2017 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	1,084
1.125% Notes due 2017 | Carrying Amount
Non-Current Debt
Non-Current Debt	706
1.125% Notes due 2017 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	710
5.15% Debentures due 2018 | Carrying Amount
Non-Current Debt
Non-Current Debt	899
5.15% Debentures due 2018 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	995
1.65% Notes due 2018 | Carrying Amount
Non-Current Debt
Non-Current Debt	609
1.65% Notes due 2018 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	616
4.75% Notes due 2019 (1B Euro 1.1267) | Carrying Amount
Non-Current Debt
Non-Current Debt	1,123
4.75% Notes due 2019 (1B Euro 1.1267) | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	1,322
1.875% Notes due 2019 | Carrying Amount
Non-Current Debt
Non-Current Debt	510
1.875% Notes due 2019 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	517
3% Zero Coupon Convertible Subordinated Debentures due in 2020 | Carrying Amount
Non-Current Debt
Non-Current Debt	140
3% Zero Coupon Convertible Subordinated Debentures due in 2020 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	181
2.95% Debentures due 2020 | Carrying Amount
Non-Current Debt
Non-Current Debt	545
2.95% Debentures due 2020 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	585
3.55% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	448
3.55% Notes due 2021 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	487
2.45% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	350
2.45% Notes due 2021 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	357
6.73% Debentures due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	250
6.73% Debentures due 2023 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	326
3.375% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	811
3.375% Notes due 2023 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	856
5.50% Notes due 2024 (500 MM GBP 1.5215) | Carrying Amount
Non-Current Debt
Non-Current Debt	756
5.50% Notes due 2024 (500 MM GBP 1.5215) | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	940
6.95% Notes due 2029 | Carrying Amount
Non-Current Debt
Non-Current Debt	297
6.95% Notes due 2029 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	426
4.95% Debentures due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	500
4.95% Debentures due 2033 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	571
4.375% Notes due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	864
4.375% Notes due 2033 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	932
5.95% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	996
5.95% Notes due 2037 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	1,275
5.85% Debentures due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	700
5.85% Debentures due 2038 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	898
4.50% Debentures due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	541
4.50% Debentures due 2040 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	585
4.85% Notes due 2041 | Carrying Amount
Non-Current Debt
Non-Current Debt	298
4.85% Notes due 2041 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	345
4.50% Notes due 2043 | Carrying Amount
Non-Current Debt
Non-Current Debt	499
4.50% Notes due 2043 | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	539
Other | Carrying Amount
Non-Current Debt
Non-Current Debt	32
Other | Estimate of Fair Value, Fair Value Disclosure
Non-Current Debt
Non-Current Debt	$ 32

Fair Value Measurements (Deta34

Fair Value Measurements (Details Textuals) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 27, 2015	Sep. 28, 2014	Sep. 27, 2015	Sep. 28, 2014	Dec. 28, 2014
Derivative [Line Items]
Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax	$ 130		$ 130		$ 141
Maximum Length of Time Hedged in Foreign Currency Cash Flow Hedge			18 months
Fair Value Measurements (Textuals)
Reclassification of foreign exchange contracts into earnings, period			next 12 months
Weighted average interest rate on non-current debt	4.18%		4.18%
Excess Of Fair Value Over Carrying Value Of Debt					2,200
Other income/(expense), net, related to foreign exchange contracts, non hedging	$ (8)	$ (2)	$ 32	$ (48)
Interest Rate Contract
Derivative [Line Items]
Derivative notional amounts outstanding	2,200		2,200
Foreign exchange contracts
Derivative [Line Items]
Derivative notional amounts outstanding	27,800		27,800
Cross currency interest rate swaps
Derivative [Line Items]
Derivative notional amounts outstanding	2,400		2,400
Equity Securities [Member]
Derivative [Line Items]
Available-for-sale Securities, Equity Securities	531		531		284
Fair Value Measurements (Textuals)
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	648		648		406
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	$ 49		$ 49		$ 11

Fair Value Measurements - Cash

Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Millions		Sep. 27, 2015	Dec. 28, 2014	Sep. 28, 2014	Dec. 29, 2013
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Estimated Fair Value	[1]	$ 5,269
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		13,639	$ 14,523	$ 13,818	$ 20,927
Marketable securities		23,667	$ 18,566
Held-to-maturity Securities
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount		32,037
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		5
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value		32,042
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		13,639
Marketable securities		18,398
Held-to-maturity Securities | Cash
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount		1,976
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value		1,976
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		1,976
Held-to-maturity Securities | U.S. Gov't Securities(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[2]	15,694
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		5
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[2]	15,699
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[2]	1,700
Marketable securities	[2]	13,994
Held-to-maturity Securities | Other Sovereign Securities(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[2]	2,737
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[2]	2,737
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[2]	1,192
Marketable securities	[2]	1,545
Held-to-maturity Securities | U.S. Reverse repurchase agreements(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[2]	3,015
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[2]	3,015
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[2]	3,015
Held-to-maturity Securities | Other Reverse repurchase agreements(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[2]	2,179
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[2]	2,179
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[2]	2,179
Held-to-maturity Securities | Corporate debt securities(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[2]	4,237
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[2]	4,237
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[2]	1,378
Marketable securities	[2]	2,859
Held-to-maturity Securities | Money market funds
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount		1,358
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value		1,358
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		1,358
Held-to-maturity Securities | Time deposits(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[2]	841
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[2]	841
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[2]	841
Available-for-sale Securities
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	[3]	5,257
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[3]	16
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[3]	(4)
Available-for-sale Securities - Estimated Fair Value	[3]	5,269
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[3]	0
Marketable securities	[3]	5,269
Available-for-sale Securities | U.S. Gov't Securities(1)
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	[3]	4,255
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[3]	14
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[3]	(1)
Available-for-sale Securities - Estimated Fair Value	[3]	4,268
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		0
Marketable securities	[3]	4,268
Available-for-sale Securities | Corporate debt securities(1)
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	[3]	1,002
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[3]	2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[3]	(3)
Available-for-sale Securities - Estimated Fair Value	[3]	1,001
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		0
Marketable securities	[3]	$ 1,001
[1]	Classified as current marketable securities
[2]	Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings
[3]	Available for sale securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.

Income Taxes (Details Textuals)

Income Taxes (Details Textuals) - USD ($) $ in Billions	9 Months Ended
	Sep. 27, 2015	Sep. 28, 2014
Income Tax (Textuals)
Effective Income Tax Rate, Continuing Operations	21.00%	22.70%
Unrecognized tax benefits	$ 2.6
OCD [Member]
Income Tax (Textuals)
Other tax item percent		41.00%

Pensions and Other Postretire37

Pensions and Other Postretirement Benefits (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2015	Sep. 28, 2014	Sep. 27, 2015	Sep. 28, 2014
Retirement Plans
Components of net periodic benefit cost
Service cost	$ 247	$ 197	$ 744	$ 594
Interest cost	246	255	743	768
Expected return on plan assets	(451)	(403)	(1,361)	(1,212)
Amortization of prior service cost/(credit)	0	1	1	4
Recognized actuarial losses	186	115	560	346
Curtailments and settlements	0	(11)	4	(11)
Net periodic benefit cost	228	154	691	489
Other Benefit Plans
Components of net periodic benefit cost
Service cost	64	52	193	158
Interest cost	46	50	139	149
Expected return on plan assets	(2)	(2)	(5)	(5)
Amortization of prior service cost/(credit)	(8)	(8)	(25)	(25)
Recognized actuarial losses	50	33	150	101
Curtailments and settlements	0	0	0	0
Net periodic benefit cost	$ 150	$ 125	$ 452	$ 378

Pensions and Other Postretire38

Pensions and Other Postretirement Benefit (Details Textuals) $ in Millions	9 Months Ended
	Sep. 27, 2015USD ($)
U.S. retirement plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 316
International retirement plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 23

Accumulated Other Comprehensi39

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2015	Sep. 28, 2014	Sep. 27, 2015	Sep. 28, 2014
Foreign Currency Translation
Beginning Balance			$ (4,803)
Net change	$ (1,069)	$ (2,400)	(2,729)	$ (2,499)
Ending Balance	(7,532)		(7,532)
Gain /(Loss) on Securities
Beginning Balance			257
Net change	(90)	(36)	140	5
Ending Balance	397		397
Employee Benefit Plans
Begining Balance			(6,317)
Net change	154	96	461	287
Ending Balance	(5,856)		(5,856)
Gain/(Loss) on Derivatives & Hedges
Beginning Balance			141
Net change	198	(35)	(11)	(315)
Ending Balance	130		130
Total Accumulated Other Comprehensive Income (Loss)
Beginning Balance			(10,722)
Net change	(807)	$ (2,375)	(2,139)	$ (2,522)
Ending Balance	$ (12,861)		$ (12,861)

Earnings Per Share (Details)

Earnings Per Share (Details) - $ / shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2015	Sep. 28, 2014	Sep. 27, 2015	Sep. 28, 2014
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share	$ 1.21	$ 1.69	$ 4.39	$ 4.89
Average shares outstanding — basic	2,768.4	2,814.4	2,774.8	2,822
Potential shares exercisable under stock option plans	129.4	148.4	129.1	148.8
Less: shares which could be repurchased under treasury stock method	(92.8)	(101.2)	(89)	(102.3)
Convertible debt shares	2.2	2.7	2.2	2.7
Average shares outstanding — diluted	2,807.2	2,864.3	2,817.1	2,871.2
Diluted earnings per share	$ 1.20	$ 1.66	$ 4.33	$ 4.81

Earnings Per Share (Details Tex

Earnings Per Share (Details Textuals) - shares shares in Millions	3 Months Ended	9 Months Ended
	Sep. 27, 2015	Sep. 27, 2015
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	20	20

Segments of Business and Geog42

Segments of Business and Geographic Areas (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2015	Sep. 28, 2014	Sep. 27, 2015	Sep. 28, 2014
Sales by segment of business
Sales	$ 17,102	$ 18,467	$ 52,263	$ 56,077
Percentage Change In Sales By Segment Of Business	(7.40%)		(6.80%)
United States
Sales by segment of business
Sales	$ 8,791	8,842	$ 26,394	26,178
Percentage Change In Sales By Segment Of Business	(0.60%)		0.80%
International
Sales by segment of business
Sales	$ 8,311	9,625	$ 25,869	29,899
Percentage Change In Sales By Segment Of Business	(13.70%)		(13.50%)
Consumer
Sales by segment of business
Sales	$ 3,314	3,589	$ 10,187	10,890
Percentage Change In Sales By Segment Of Business	(7.70%)		(6.50%)
Consumer | United States
Sales by segment of business
Sales	$ 1,277	1,173	$ 3,991	3,802
Percentage Change In Sales By Segment Of Business	8.90%		5.00%
Consumer | International
Sales by segment of business
Sales	$ 2,037	2,416	$ 6,196	7,088
Percentage Change In Sales By Segment Of Business	(15.70%)		(12.60%)
Pharmaceutical
Sales by segment of business
Sales	$ 7,694	8,307	$ 23,366	24,314
Percentage Change In Sales By Segment Of Business	(7.40%)		(3.90%)
Pharmaceutical | United States
Sales by segment of business
Sales	$ 4,509	4,723	$ 13,423	13,076
Percentage Change In Sales By Segment Of Business	(4.50%)		2.70%
Pharmaceutical | International
Sales by segment of business
Sales	$ 3,185	3,584	$ 9,943	11,238
Percentage Change In Sales By Segment Of Business	(11.10%)		(11.50%)
Medical Devices
Sales by segment of business
Sales	$ 6,094	6,571	$ 18,710	20,873
Percentage Change In Sales By Segment Of Business	(7.30%)		(10.40%)
Medical Devices | United States
Sales by segment of business
Sales	$ 3,005	2,946	$ 8,980	9,300
Percentage Change In Sales By Segment Of Business	2.00%		(3.40%)
Medical Devices | International
Sales by segment of business
Sales	$ 3,089	$ 3,625	$ 9,730	$ 11,573
Percentage Change In Sales By Segment Of Business	(14.80%)		(15.90%)

Segments of Business and Geog43

Segments of Business and Geographic Areas (Details 1) - USD ($) $ in Millions		3 Months Ended			9 Months Ended
		Sep. 27, 2015	Jun. 28, 2015	Sep. 28, 2014	Sep. 27, 2015	Sep. 28, 2014
Segment Reporting Information [Line Items]
Net gain on sale of assets/businesses					$ 1,274	$ 2,336
Asset write-downs					$ 367	259
Percentage Change in Operating Income Loss		(39.50%)			(13.60%)
Earnings before provision for taxes on income		$ 4,122		$ 6,810	$ 15,438	17,860
Consumer
Segment Reporting Information [Line Items]
Net gain on sale of assets/businesses		229			229	$ 388
Pharmaceutical
Segment Reporting Information [Line Items]
Net gain on sale of assets/businesses			$ 981		981
Other Expenses				$ 220		$ 220
Litigation Expense					136
Medical Devices
Segment Reporting Information [Line Items]
Net gain on sale of assets/businesses				$ 1,948		$ 1,948
Litigation Expense		409		225		501
Asset write-downs		300			300
Integration costs related to a business acquisition				167	113	429
Product Liability Accrual, Period Expense				$ 126	148	$ 126
Corporate and Other
Segment Reporting Information [Line Items]
Litigation Expense
Operating Segments [Member]
Segment Reporting Information [Line Items]
Total Segment Operating Income		$ 4,378		$ 7,053	$ 16,228	$ 18,578
Percentage Change in Operating Income Loss		(37.90%)			(12.60%)
Operating Segments [Member] | Consumer
Segment Reporting Information [Line Items]
Total Segment Operating Income	[1]	$ 811		407	$ 1,772	1,588
Percentage Change in Operating Income Loss		99.30%			11.60%
Operating Segments [Member] | Pharmaceutical
Segment Reporting Information [Line Items]
Total Segment Operating Income	[2]	$ 2,732		3,247	$ 9,816	9,921
Percentage Change in Operating Income Loss		(15.90%)			(1.10%)
Operating Segments [Member] | Medical Devices
Segment Reporting Information [Line Items]
Total Segment Operating Income	[3]	$ 835		3,399	$ 4,640	7,069
Percentage Change in Operating Income Loss		(75.40%)			(34.40%)
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Total Segment Operating Income	[4]	$ 256		$ 243	$ 790	$ 718
[1]	Includes a gain of $229 million from the divestiture of the SPLENDA® brand recorded in the fiscal third quarter and fiscal nine months of 2015. Includes a gain of $388 million from the divestiture of the K-Y® brand recorded in the fiscal nine months of 2014.
[2]	Includes litigation expense of $136 million in the fiscal nine months of 2015. Includes a gain of $981 million recorded in the fiscal nine months of 2015 from the divestiture of the U.S. license rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol extended-release tablets), and NUCYNTA® (tapentadol) oral solution. Includes an additional year of the Branded Prescription Drug Fee of $220 million recorded in the fiscal third quarter and fiscal nine months of 2014.
[3]	Includes litigation expense of $409 million related to product liability and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal third quarter of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $225 million, Synthes integration costs of $167 million and $126 million for costs associated with the DePuy ASRTM Hip program recorded in the fiscal third quarter of 2014. Includes $148 million for costs associated with the DePuy ASRTM Hip program, Synthes integration costs of $113 million and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal nine months of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $501 million, Synthes integration costs of $429 million and $126 million for costs associated with the DePuy ASRTM Hip program recorded in the fiscal nine months of 2014.
[4]	Amounts not allocated to segments include interest income/expense and general corporate income/expense.

Segments of Business and Geog44

Segments of Business and Geographic Areas (Details 2) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2015	Sep. 28, 2014	Sep. 27, 2015	Sep. 28, 2014
Sales by geographic area
Sales	$ 17,102	$ 18,467	$ 52,263	$ 56,077
Percentage Change In Sales By Geographic Area	(7.40%)		(6.80%)
UNITED STATES
Sales by geographic area
Sales	$ 8,791	8,842	$ 26,394	26,178
Percentage Change In Sales By Geographic Area	(0.60%)		0.80%
Europe
Sales by geographic area
Sales	$ 3,802	4,446	$ 11,993	14,387
Percentage Change In Sales By Geographic Area	(14.50%)		(16.60%)
Western Hemisphere, excluding U.S.
Sales by geographic area
Sales	$ 1,463	1,820	$ 4,603	5,378
Percentage Change In Sales By Geographic Area	(19.60%)		(14.40%)
Asia-Pacific, Africa
Sales by geographic area
Sales	$ 3,046	$ 3,359	$ 9,273	$ 10,134
Percentage Change In Sales By Geographic Area	(9.30%)		(8.50%)

Business Combinations and Div45

Business Combinations and Divestitures (Details) - USD ($) $ in Millions	Oct. 02, 2015	Sep. 27, 2015	Jun. 28, 2015	Sep. 28, 2014	Sep. 27, 2015	Sep. 28, 2014
Business Acquisition [Line Items]
Net gain on sale of assets/businesses					$ 1,274	$ 2,336
Nucynta [Member]
Business Acquisition [Line Items]
Proceeds from Sales of Business, Affiliate and Productive Assets			$ 1,050
Cordis | Inventory [Member]
Business Acquisition [Line Items]
Disposal Group, Including Discontinued Operation, Assets, Current		$ 173			173
Cordis | Property, Plant and Equipment [Member]
Business Acquisition [Line Items]
Assets Held-for-sale, Other, Noncurrent		104			104
Cordis | Other Intangible Assets [Member]
Business Acquisition [Line Items]
Assets Held-for-sale, Other, Noncurrent		59			59
Cordis | Goodwill
Business Acquisition [Line Items]
Assets Held-for-sale, Other, Noncurrent		98			98
OCD [Member] | Inventory [Member]
Business Acquisition [Line Items]
Disposal Group, Including Discontinued Operation, Assets, Current		42			42
OCD [Member] | Property, Plant and Equipment [Member]
Business Acquisition [Line Items]
Assets Held-for-sale, Other, Noncurrent		107			107
Pharmaceutical
Business Acquisition [Line Items]
Net gain on sale of assets/businesses			$ 981		981
Medical Devices
Business Acquisition [Line Items]
Net gain on sale of assets/businesses				$ 1,948		$ 1,948
Medical Devices | OCD [Member]
Business Acquisition [Line Items]
Proceeds from Sales of Business, Affiliate and Productive Assets				$ 4,000
Consumer
Business Acquisition [Line Items]
Net gain on sale of assets/businesses		$ 229			$ 229	$ 388
Subsequent Event [Member] | Cordis
Business Acquisition [Line Items]
Proceeds from Sales of Business, Affiliate and Productive Assets	$ 2,000

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 29, 2015USD ($)	Sep. 27, 2015USD ($)patentsclaimant
Xarelto [Member]
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants | claimant		3,000
ASR
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants | claimant		6,300
Pinnacle Acetabular Cup System
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants | claimant		8,300
Risperdal
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants | claimant		5,400
Pelvic Meshes
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants | claimant		44,400
settled litigation | misdemeanor violation [Member]
Legal Proceeding (Textuals)
Litigation Settlement, Amount		$ 20,000
settled litigation | Forfeiture [Member]
Legal Proceeding (Textuals)
Litigation Settlement, Amount		5,000
Pending Litigation | Restitution
Legal Proceeding (Textuals)
Litigation Settlement, Amount		45,000
Pending Litigation | Civil penalties
Legal Proceeding (Textuals)
Litigation Settlement, Amount		6,500
Pending Litigation | Risperdal | Civil penalties
Legal Proceeding (Textuals)
Litigation Settlement, Amount		327,100
Pending Litigation | Risperdal | Civil penalties
Legal Proceeding (Textuals)
Litigation Settlement, Amount	$ 136,000	124,000
Investigative Demands [Member]
Legal Proceeding (Textuals)
Litigation Settlement, Expense		$ 4,000
DePuy ASR U.S. | settled litigation
Legal Proceeding (Textuals)
Number of patients in settlement		8,000
Tyco [Member] | Pending Litigation
Legal Proceeding (Textuals)
Litigation Settlement, Amount		$ 176,000
Roche Diagnostics [Member]
Legal Proceeding (Textuals)
Loss Contingency, Patents Allegedly Infringed, Number | patents		2
Baxter International [Member]
Legal Proceeding (Textuals)
Loss Contingency, Patents Allegedly Infringed, Number | patents		6
Bonutti Skeletal Innovations [Member]
Legal Proceeding (Textuals)
Loss Contingency, Patents Allegedly Infringed, Number | patents		6
Risperdal | settled litigation
Legal Proceeding (Textuals)
Litigation Settlement, Amount		$ 7,750
Risperdal | Pending Litigation
Legal Proceeding (Textuals)
Litigation Settlement, Amount		1,200,000
Risperdal | Pending Litigation | Legal professional fees
Legal Proceeding (Textuals)
Litigation Settlement, Amount		181,000
alleged consumer fraud | Pending Litigation
Legal Proceeding (Textuals)
Litigation Settlement, Amount		4,500
medicare fraud | Pending Litigation
Legal Proceeding (Textuals)
Litigation Settlement, Amount		257,700
medicare fraud | Pending Litigation | Legal professional fees
Legal Proceeding (Textuals)
Litigation Settlement, Amount		$ 73,000
DePuy ASR U.S.Second Agreement [Member] | Pending Litigation
Legal Proceeding (Textuals)
Number of patients in settlement		1,800
Guidant [Member]
Legal Proceeding (Textuals)
Litigation Settlement, Amount		$ (600,000)